<DOC>
	<DOC>NCT01773083</DOC>
	<brief_summary>The purpose of this international multi-center double-blind randomized placebo-controlled trial is to determine the effect of nebulized heparin, compared to placebo, on the number of ventilator-free days at day 28, in burn patients with confirmed inhalation trauma requiring mechanical ventilation.</brief_summary>
	<brief_title>Trial of Nebulized Heparin Versus Placebo for Inhalation Trauma</brief_title>
	<detailed_description />
	<mesh_term>Wounds and Injuries</mesh_term>
	<mesh_term>Respiratory Aspiration</mesh_term>
	<mesh_term>Burns</mesh_term>
	<mesh_term>Calcium heparin</mesh_term>
	<mesh_term>Heparin</mesh_term>
	<criteria>Informed consent Age &gt; 18 years Need for invasive mechanical ventilation Confirmed inhalation trauma (bronchoscopically) &gt; 36 hours after trauma Receiving invasive ventilation &gt; 24 hours Expected duration of mechanical ventilation &lt; 24 hours Chronic obstructive pulmonary disease GOLD stage III and IV Any history of pulmonary hemorrhage in the past 3 months Any history of significant bleeding disorder Known allergy to heparin, including heparininduced thrombocytopenia Pregnancy or breast feeding Unlikely to survive for &gt; 72 hours Total body surface area (TBSA) &gt; 60% Witnessed or proven aspiration (i.e., confirmed by bronchoscopy)</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>January 2017</verification_date>
	<keyword>Inhalation trauma</keyword>
	<keyword>pulmonary coagulopathy</keyword>
	<keyword>heparin nebulization</keyword>
	<keyword>mechanical ventilation</keyword>
</DOC>